Showing results (101-110 of 110) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Arthritis|March 12, 2015
Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional studyGrith P Eng, Klaus Bendtzen, Henning Bliddal, et al.Journal of Cellular Physiology|April 5, 2014
Hypomethylating agent 5-aza-2'-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse modelsKatia Mangano, Paolo Fagone, Klaus Bendtzen, et al.Journal of Immunological Methods|September 14, 2011
Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonistsChristophe Lallemand, Nadia Kavrochorianou, Casper Steenholdt, et al.Lancet (London, England)|October 22, 2003
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisPer Soelberg Sorensen, Christian Ross, Katja Maria Clemmesen, et al.Gut|July 24, 2013
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trialCasper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, et al.Digestive Diseases and Sciences|February 13, 2015
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing InfliximabCasper Steenholdt, Jørn Brynskov, Ole Ø Thomsen, et al.Plos One|March 18, 2016
Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In VitroJuliana Frohnert Hansen, Marianne Møller Brorson, Malene Boas, et al.Autoimmunity Reviews|March 17, 2020
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitorsCaterina Bodio, Claudia Grossi, Francesca Pregnolato, et al.Plos One|December 24, 2010
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcomeMarieke J H Coenen, Christian Enevold, Pilar Barrera, et al.NEJM Evidence|February 6, 2024
Discontinuation of Infliximab Therapy in Patients with Crohn's DiseaseSine Buhl, Casper Steenholdt, Jørn Brynskov, et al.Pageof 11